NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
Clinical Trials
9 trialsNCT06109272 2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3 Recruiting
NCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
NCT05976568 2023-08-04
A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Qilu Pharmaceutical Co., Ltd.
Phase 2/3 Not yet recruiting
NCT05408221 2023-03-10
HCC
Shandong New Time Pharmaceutical Co., LTD
Phase 2/3 Recruiting
NCT03794440 2021-01-22
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2/3 Unknown
NCT03592706 2020-04-16
Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy
Ivy Life Sciences, Co., Ltd
Phase 2/3 Unknown
NCT00034333 2005-06-24
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer
FeRx
Phase 2/3 Terminated
NCT00057382 2005-06-24
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Tularik
Phase 2/3 Terminated